NICE Recommends Mepolizumab for Uncontrolled COPD
NICE has recommended mepolizumab as an add-on treatment for adults with uncontrolled COPD and raised blood eosinophils. This biologic therapy aims to reduce exacerbations and improve patient outcomes. The decision is expected to benefit approximately 30,000 individuals in England suffering from this condition.
- ▪NICE recommends mepolizumab for uncontrolled COPD with raised blood eosinophils in adults.
- ▪Mepolizumab is administered subcutaneously every 4 weeks and targets interleukin-5 to reduce eosinophil levels.
- ▪Clinical trials showed that mepolizumab plus triple therapy significantly reduced moderate or severe exacerbations compared to triple therapy alone.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/nice-recommends-mepolizumab-uncontrolled-copd-2026a1000hzz?src=rss |
| Publication time | Fri, 29 May 2026 10:17:27 EDT |
| Retrieval time | 2026-05-29T14:20:01.346Z |
| Last seen | 2026-05-29T14:20:01.346Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | xYVxSfYnwj-B |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The National Institute for Health and Care Excellence (NICE) has recommended mepolizumab for the treatment of chronic obstructive pulmonary disease (COPD). In its final draft guidance, NICE said that mepolizumab was recommended as an add-on maintenance treatment option for uncontrolled COPD with raised blood eosinophils in adults, if they were receiving triple inhaler therapy — including an inhaled corticosteroid (ICS), a long-acting beta-2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA). Uncontrolled COPD is defined as one or more severe exacerbations or two or more moderate exacerbations in the previous 12 months.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
